UPC appeals court hands Amgen a win in cholesterol dispute

The Court of Appeal has overturned a ruling that revoked the pharma company’s cholesterol-lowering antibody patent, clarifying key principles for assessing inventive step.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UPC issues first decision on second medical use

13 May 2025 Court of First Instance rules on Sanofi v Amgen antibodies dispute | Claims dismissed as “unfounded” and lacking in evidence | All parties ordered to pay costs totalling €45m ($50m).

Unified Patent Court

Sanofi and Regeneron triumph in UPC decision against Amgen

16 July 2024 UPC’s Munich Central Division revokes Amgen's patent | Decision stems from a revocation action initiated by Sanofi last year | Court's ruling focused on interpretations of patent claims and principles of inventive step.

Big Pharma

Amgen v Sanofi/Regeneron in Japan: Function, sequence, mechanism

19 March 2024 Amgen patents declared valid in Germany and Japan have also been deemed invalid by the European Patent Office, US Supreme Court, and in a separate Japan decision: but why? Takanori Abe of Abe & Partners examines the details.

More features

Squires affirms USPTO’s stance on AI with revised guidance

UPC judges call for greater female advocacy at court

The clinical trial dilemma: Navigating European practice

Novartis counsel on managing patents at a $50bn company

Biotech cleared to make biosimilar of $6bn treatment after landmark ruling

Ex-Teva counsel and FDA regulatory specialist returns to private practice

Use of genAI to draft patents ‘a big concern’: CIPA’s AI chair

What people talked about at London Life Sciences Week

UPC appeals court hands Amgen a win in cholesterol dispute

More on this story

Editor's picks

Editor's picks

More features